Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSE:QLT)‘s stock had its “accumulate” rating reiterated by equities research analysts at Bloom Burton in a report released on Monday.

Several other equities research analysts also recently weighed in on the stock. ValuEngine downgraded shares of Novelion Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, June 2nd. Zacks Investment Research downgraded shares of Novelion Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, June 13th.

Novelion Therapeutics (NVLN) opened at 10.04 on Monday. The stock’s market capitalization is $186.77 million. Novelion Therapeutics has a one year low of $6.10 and a one year high of $13.80. The company has a 50-day moving average of $9.14 and a 200-day moving average of $9.24.

ILLEGAL ACTIVITY NOTICE: This piece was published by Watch List News and is owned by of Watch List News. If you are viewing this piece on another site, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be read at https://www.watchlistnews.com/novelion-therapeutics-inc-nvln-earns-accumulate-rating-from-bloom-burton/1380485.html.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Stonepine Capital Management LLC boosted its position in Novelion Therapeutics by 2.4% in the first quarter. Stonepine Capital Management LLC now owns 1,560,487 shares of the biotechnology company’s stock worth $16,760,000 after buying an additional 36,453 shares in the last quarter. Highbridge Capital Management LLC boosted its position in Novelion Therapeutics by 190.8% in the first quarter. Highbridge Capital Management LLC now owns 625,268 shares of the biotechnology company’s stock worth $6,716,000 after buying an additional 410,268 shares in the last quarter. FMR LLC bought a new position in Novelion Therapeutics during the fourth quarter worth about $5,164,000. Renaissance Technologies LLC bought a new position in Novelion Therapeutics during the fourth quarter worth about $2,803,000. Finally, Gilder Gagnon Howe & Co. LLC boosted its position in Novelion Therapeutics by 27.4% in the first quarter. Gilder Gagnon Howe & Co. LLC now owns 331,599 shares of the biotechnology company’s stock worth $3,561,000 after buying an additional 71,409 shares in the last quarter. 72.63% of the stock is owned by institutional investors and hedge funds.

About Novelion Therapeutics

Novelion Therapeutics Inc, formerly QLT Inc, is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development.

Receive News & Ratings for Novelion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novelion Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.